{"id":"W2466927139","doi":"10.1080/13543776.2016.1206080","title":"Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015)","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"Fondation Leducq","keywords":"PCSK9; Alirocumab; Evolocumab; Kexin; Proprotein convertase; Dyslipidemia; Medicine; Pharmacology; Monoclonal antibody; Cholesterol; LDL receptor; Antibody; Internal medicine; Immunology; Lipoprotein; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000623994,0.0005942097,0.0009380673,0.002460952,0.0002679438,0.001168902,0.0005340066,0.001006133,0.007181922],"category_scores_gemma":[0.001005274,0.0002025326,0.0007471264,0.00245108,0.0002710866,0.001507212,0.000560586,0.001356351,0.002102587],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006509505,"about_ca_system_score_gemma":0.001482034,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008657954,"about_ca_topic_score_gemma":0.001876344,"domain_scores_codex":[0.9997504,0.00003493222,0.00003704969,0.00003825794,0.0001105155,0.00002883309],"domain_scores_gemma":[0.9996036,0.0001648812,0.00008246543,0.000007168544,0.0001168742,0.00002506611],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008085599,0.00005236011,0.0001348873,0.01943889,0.00008841042,0.0002554381,0.00007379996,0.0002254743,0.001328994,0.003938598,0.0492129,0.9251693],"study_design_scores_gemma":[0.00002973237,0.0001123458,0.0007764707,0.008141415,0.0002233454,0.001225164,0.00007086651,0.00009873017,0.0003737918,0.001810757,0.9871174,0.00002007771],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002034965,0.9971439,0.00009803886,0.0008510457,0.0003471498,0.000006093775,0.00003790402,0.000007057957,0.001305267],"genre_scores_gemma":[0.0008343521,0.9976727,0.0001324765,0.0003775658,0.000268443,0.000005035476,0.00004853345,0.000001249051,0.0006596654],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007181922,"threshold_uncertainty_score":0.02402592,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08188793832644997,"score_gpt":0.3603073481168442,"score_spread":0.2784194097903943,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}